Figures
- FIGURE 1
Schematic illustration of the experimental test facilities that were used to measure aerosol delivery (%) and fugitive medical aerosol emissions from aerosol therapy delivery using a mouthpiece and holding chamber with concurrent a) high-flow nasal oxygen and b) low-flow nasal oxygen. VMN: vibrating mesh nebuliser; OPS: optical particle sizer.
- FIGURE 2
a) Aerosol drug delivery from a vibrating mesh nebuliser (VMN) at dry side of humidifier via cannula, and with aerosol holding chamber at 0, 2 and 6 L·min−1 during low-flow nasal oxygen (LFNO) at 0, 2, 3.5, 5, 7.5 and 10 L·min−1; and b) inhaled aerosol delivery efficiency (mean±sd %) at trachea from VMN at adapter and aerosol holding chamber at 0, 2 and 6 L·min−1 in model of spontaneously breathing adult patient with high-flow nasal oxygen (HFNO) gas flow of 10, 30, 50 and 60 L·min−1. MP: mouthpiece.
- FIGURE 3
Mean aerosol concentrations against time measured at a) 0.8 m and b) 2.20 m with 0 L·min−1 supplemental air flow through the aerosol holding chamber and c) 0.8 m and d) 2.20 m with 6 L·min−1 supplemental air flow through the aerosol holding chamber. VMN: vibrating mesh nebuliser; MP: mouthpiece; LFNO: low-flow nasal oxygen; HFNO: high-flow nasal oxygen.
Tables
- TABLE 1
Fugitive aerosol characterisation test details
Supplemental air flow rate in aerosol chamber 0 L·min−1 6 L·min−1 LFNO circuit 2 10 2 10 HFNO circuit 10 60 10 60 LFNO: low-flow nasal oxygen; HFNO: high-flow nasal oxygen.
Supplementary Material
Please note: supplementary material is not edited by the Editorial Office, and is uploaded as it has been supplied by the author.
Supplementary material 00220-2022.SUPPLEMENT
